AngioDynamics to Sponsor Symposium on First Human Clinical Experience with IRE TechnologyQUEENSBURY, N.Y.--(BUSINESS WIRE)--Jan. 16, 2009
(NASDAQ:ANGO), a leading provider of
innovative medical devices used by interventional radiologists,
nephrologists and surgeons for the minimally invasive treatment of
cancer and peripheral vascular disease, announced today that it will
sponsor a symposium in New York City
on January 22
during which doctors
who have performed procedures using the Company's recently-introduced
system will share their experiences and patient outcomes.
NanoKnife is the first product offered by AngioDynamics that uses the
new, potentially groundbreaking irreversible electroporation (IRE)
technology. IRE technology is a non-thermal ablation technique for the
resection of soft tissue. It has been described as "surgery at the
cellular level." The NanoKnife system uses electrical fields to create
nano-scale defects in the membranes of targeted soft tissue, causing
cell death only in the targeted tissue, without destroying critical
structures such as ducts, blood vessels and nerves nearby.
For further information, please contact Jenifer Kirtland at (415)
896-2005 or Chris Gale at (646) 201-5431.
AngioDynamics, Inc. is a leading provider of innovative medical devices
used by interventional radiologists, surgeons, and other physicians for
the minimally invasive treatment of cancer and peripheral vascular
disease. The Company's diverse product line includes market-leading
radiofrequency ablation and irreversible electroporation resection
systems, vascular access products, angiographic products and
accessories, dialysis products, angioplasty products, drainage products,
thrombolytic products, embolization products and venous products. More
information is available at www.angiodynamics.com.
In the United States, NanoKnife has been cleared by the FDA for use in
the surgical ablation of soft tissue. This document may discuss the use
of NanoKnife for specific clinical indications for which it is not
cleared in the United States at this time.
CONTACT: AngioDynamics, Inc.
D. Joseph Gersuk, CFO, 800-772-6446 ext. 1608
EVC Group, Inc.Doug Sherk, 415-896-6820 (Investor Relations)
Jenifer Kirtland, 415-896-6820 (Investor Relations)
Chris Gale, 646-201-5431 (Media)
Source: AngioDynamics Inc.